Dihexa Side Effects: What the Evidence Actually Shows

Dihexa side effects have never been measured in a human being — not in a first-in-human study, not in a case series, not in a single published report. The entire evidence base for this angiotensin IV analog is rodent behavior, mouse brain tissue, and cells in culture, and two of those papers now carry editorial flags, one a full retraction. That earns a page of its own: a compound sold for human cognition, marketed on a potency claim that appears nowhere in its own literature. Here is what the studies say, what they never asked, and where the safety sentences about dihexa come from.

In This Guide

• What Is Dihexa?
• How It’s Thought to Work
• The Entire Evidence Base: Four Preclinical Papers
• The Retraction and the Expression of Concern
• The Side-Effect Dataset That Doesn’t Exist
• The Growth-Factor Question: HGF and c-Met
• “Orally Active”: What That Phrase Established
• The Potency Claim Nobody Has Tested
• Why “No Reported Side Effects” Isn’t “No Side Effects”
• What Users Report: Self-Reported Effects From Reddit
• Doses: What the Studies Actually Administered
• Stacking Dihexa: The Missing Studies
• Where Rodent Data Stops: The Research-Product Reality
• Sourcing and Verification
• US Regulatory Status
• Frequently Asked Questions
• Glossary of Terms

What Is Dihexa?

Dihexa is N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, a chemically hardened fragment of angiotensin IV. Angiotensin IV peptides were long recognized as procognitive agents, but development stalled because they degrade fast and cross neither the gut nor the blood-brain barrier. Researchers cut the parent peptide to the three N-terminal amino acids carrying the activity, Nle-Tyr-Ile, then modified the ends to raise hydrophobicity and reduce hydrogen bonding. The result was an orally active, blood-barrier permeant, metabolically stabilized analog (PMID 23055539). The research market sells it as a nootropic, alongside the compounds in our peptides for brain function coverage. Every study behind it ran on rodents and cells.

How It’s Thought to Work

Two mechanisms appear in the literature. The famous one: dihexa binds with high affinity to hepatocyte growth factor (HGF) and induces phosphorylation of c-Met, HGF’s receptor, at subthreshold concentrations of HGF. It also induced hippocampal spinogenesis and synaptogenesis similar to HGF itself; an HGF antagonist and a short hairpin RNA directed at c-Met blocked those effects, and an HGF antagonist delivered into the brain blocked oral dihexa’s effect in the Morris water maze (PMID 25187433). That paper has since been retracted. The second comes from an independent group: in APP/PS1 mice dihexa activated the PI3K/AKT pathway, and wortmannin, a PI3K inhibitor, significantly reversed its anti-inflammatory and anti-apoptotic effects (PMID 34827486).

The Entire Evidence Base: Four Preclinical Papers

The 2013 analog-screening paper produced dihexa and reported that it reversed scopolamine-induced deficits in Morris water maze performance, augmented hippocampal synaptogenesis, and showed antidementia activity in the scopolamine and aged rat models (PMID 23055539). The 2021 study gave oral dihexa to APP/PS1 mice and found restored spatial learning, increased neuronal cells and SYP protein expression on Nissl staining, decreased activation of astrocytes and microglia, markedly reduced the pro-inflammatory cytokines IL-1β and TNF-α, and increased anti-inflammatory IL-10 (PMID 34827486). That abstract reports directions of change, not magnitudes, so we cannot give you a number for any of them.

The fourth is a systematic review, and its design is the point: it screened 450 articles, of which 32 met inclusion criteria, all experimental non-human studies. Seven of 11 studies in normal animals found angiotensin IV benefited passive or conditioned avoidance and object recognition; in cognitive-deficit models, eight of nine found angiotensin IV and its analogs — Nle1-Ang IV, dihexa, LVV-hemorphin-7 — improved spatial working memory and passive avoidance (PMID 29733881). That is family-level plausibility about animal memory, not a safety number. Borrowing a family’s reputation is an inference, and honest pages label it as one — the rule we apply to AHK-Cu and to the brain-injury peptide CAQK.

The Retraction and the Expression of Concern

Most dihexa articles omit this, and it is no technicality. The 2014 paper that established dihexa’s HGF/c-Met mechanism is flagged in PubMed as a retracted article, with the retraction notice published in 2025, and it already carried an expression of concern from 2021 (PMID 25187433). The 2013 paper that produced dihexa carries a 2021 expression of concern as well (PMID 23055539). Two of its four papers have been formally questioned by their own journal, and the mechanism paper is withdrawn. That does not prove the biology wrong — the independent 2021 mouse study reported cognitive rescue without relying on it. It does mean the most-quoted fact about dihexa comes from a paper the literature has removed, and we have yet to see a product listing that says so.

The Side-Effect Dataset That Doesn’t Exist

A real side-effect profile needs four things: humans receiving the compound, a control group, systematic recording of everything that happens, and publication. Dihexa has none of the four. No adverse-event table exists anywhere in the scientific literature, no blood pressure or heart-rate data in people, no liver panel, no dose-limiting toxicity, no discontinuation rate. The rodent studies were built to detect cognitive improvement, not harm — maze latency, Nissl staining, cytokine levels. A safety endpoint was never the question. When we say “no data” we mean it literally, and it cuts both ways: nothing documents harm, and nothing demonstrates safety.

The Growth-Factor Question: HGF and c-Met

The abstracts raise a mechanistic question they never answer. Dihexa’s reported action is not receptor blockade or neurotransmitter tuning; it is amplification of a growth-factor system. In the 2014 work it augmented HGF-dependent cell scattering — a cell-motility readout — alongside hippocampal spinogenesis and synaptogenesis (PMID 25187433). All of it was measured in neurons, cultured cells, and rodent brains, in a compound described as orally active and blood-brain barrier permeable, which by definition means systemic exposure. What no abstract here reports is what a c-Met-amplifying compound does in tissue outside the brain. No published dihexa study reports a proliferative harm, and none looked for one. An unexamined question is not a clean result.

“Orally Active”: What That Phrase Established

Dihexa’s marketing rests heavily on two words from the 2013 paper: orally active. The phrase is accurate, and narrower than it sounds. The study established that oral delivery in rodents put enough compound past the gut and the blood-brain barrier to change behavior in a maze (PMID 23055539). It established nothing about humans: no absorbed fraction, no half-life, no metabolite profile, no exposure-response relationship. And the systematic review found this peptide family most effective administered intracerebroventricularly, directly into the brain’s ventricles (PMID 29733881) — a route available to nobody reading this.

The Potency Claim Nobody Has Tested

Dihexa is sold on a superlative: listings describe it as vastly more potent than the brain’s own growth factors, usually with a multiplier attached. Search the four papers for that figure and it is not there. The strongest characterizations in the source abstracts are qualitative: “excellent antidementia activity in the scopolamine and aged rat models” and “marked synaptogenic activity” (PMID 23055539). No human comparison exists anywhere, because no human has been dosed and measured. A potency claim about human cognition, for a compound never given to a person under observation, is not an overstatement of the evidence. It is unrelated to it.

Why “No Reported Side Effects” Isn’t “No Side Effects”

The most common safety sentence written about dihexa — “no side effects have been reported” — is technically true and structurally empty. Reporting requires a mechanism: trials with adverse-event logging, a pharmacovigilance system, published case reports. Dihexa, an unapproved compound sold outside medicine, has none of those. Someone who takes it and gets a persistent headache tells a forum or tells nobody; neither shows up in a literature search. Absence of evidence here reflects absence of surveillance, not surveillance returning a clean result. Our PE-22-28 side effects page hits the same wall, and so does humanin.

What Users Report: Self-Reported Effects From Reddit

Every safety sentence on this page rests on rodents, cells and a retraction; the only descriptions of dihexa in people are self-reports. We searched Reddit on September 5, 2026, found 97 relevant posts from 2021 to 2026, and read the comment threads of ten, across r/Nootropics, r/NooTopics, r/Peptides and r/BiohackingU. Everything below is paraphrased and linked, uses no usernames, and describes products nobody verified. With dihexa that clause dominates: the most-upvoted thread we read is a lab report showing a vendor’s product was another drug.

Product identity is the first problem, and the users know it. In 2021 a buyer sent a gram of powder sold as dihexa to a state laboratory, which found NSI-189, a different compound; the vendor answered once and went silent (r/Nootropics). A poster who had already taken it said it felt as expected, which confirmed nothing. The author of the most-commented thread calls much of it bunk and was a non-responder for years (r/NooTopics). One user’s kit dissolved readily in bacteriostatic water and did nothing (thread); others insist the real thing dissolves only in DMSO (r/Peptides).

Sleep and energy reports point in both directions. A poster on 8 mg capsules daily got immediate focus but so much energy that sleep suffered (thread); a 2021 user on 100 mg daily with Adderall and Wellbutrin also needed sleep aids (thread); a third, a month in at 5 mg, reported energy and clearer thinking (r/NooTopics). Conversely, a poster five months past a concussion was exhausted two hours after an 8 mg capsule and still dozed off at half the dose (thread).

The most repeated warning is emotional: flattening, and locking in whatever state you are in. When a bedridden poster with post-SSRI emotional numbness asked whether dihexa would restore his feelings, the top reply said it causes additional flatness and a self-described long-term user said it deepens numbness (r/NooTopics). An anhedonic user nine months off mephedrone, on 20 to 40 mg transdermally with 9-Me-BC and selegiline, felt calmer but also described depression-like sadness indistinguishable from his baseline, and later found he had taken double the intended dose (r/Nootropics). The 170-comment misconceptions thread argues that dihexa hardwires whatever you do during a week-long plasticity window; its author stopped after two doses and admits much of his mechanistic advice is pasted from a chatbot (thread). Users describing the aftermath call it long-lasting, not permanent (r/NooTopics), or gone within three weeks (thread).

Positive reports cluster around learning, and skeptics call it placebo. One poster found it otherworldly alongside sport, juggling and study, and unremarkable on a work day (r/NooTopics); another there learned faster on 5 mg capsules but felt unusually aware of minor aches for hours. The two-week reporter on 5 mg a day plus occasional modafinil feels no different yet won an unusual run of bullet-chess games (thread). Against this, posters on 5 mg for three weeks and on 20 mg weekly noticed nothing or next to nothing (r/Peptides); the fabrication thread’s top comment finds no rigorous anecdotes and blames influencer hype (thread); and the anhedonic poster conceded it “feels like a placebo, but definitely isn’t” (thread).

Cancer is the fear everyone names and nobody reports. A 2026 thread on the growing dihexa market notes that no cancer case has been reported in connection with its use; commenters replied that the real worry is accelerating an existing tumor, and argued over whether the retraction discussed on this page concerned dihexa at all (r/Nootropics). One person ruled it out for a parent who had survived cancer (thread). Nobody in ten threads describes a diagnosis. Doses have no anchor, from a 500 mcg nasal spray (thread) to single 150 mg oral doses taken recreationally (thread), with one poster planning an intravenous DMSO solution another called unfit for veins (thread).

Doses: What the Studies Actually Administered

This section is short for an unusual reason: not one of the four abstracts states a dihexa dose. The 2013 paper describes the analog series and its oral activity without giving a quantity (PMID 23055539); the 2014 paper describes orally delivered dihexa the same way. The 2021 study says only that researchers used different doses in APP/PS1 mice, orally administered, and reports that the amount of angiotensin IV in mouse tissue increased after administration compared with the WT group (PMID 34827486). We report what studies administered and nothing more, so here there is nothing to report.

Stacking Dihexa: The Missing Studies

The combinations people actually run — dihexa with Semax, with Selank, or layered into a broader nootropic protocol — have no published studies as combinations. Not sparse studies: none. The four papers tested dihexa alone; the only co-administration in the file is experimental blockade designed to switch the effect off. Stacking an unmeasured compound with other unmeasured compounds does not average the uncertainty out; it multiplies the things you cannot attribute an effect to. The adjacent evidence sits in our brain health and attention guides.

Where Rodent Data Stops: The Research-Product Reality

The research-vial problem is usually that the vial does not inherit the trials. With dihexa it is starker: there are no human trials to inherit and the mechanism paper has been retracted, so the vial rests on its own documentation. The gap shows up three ways. Identity and purity: a batch-matched COA is the only evidence a vial or capsule holds dihexa at the stated quantity. Concentration arithmetic: anyone reconstituting with bacteriostatic water does that math themselves, against no established reference dose. No reference point: there is no trial-grade dihexa experience to compare a product against, because that trial was never run.

Sourcing and Verification

For a compound with no safety literature, product quality is the only safety variable a buyer can influence, so documentation matters more here, not less. The checklist does not change: a batch-matched COA naming compound and quantity, independent third-party testing with a verifiable report number, and hard skepticism toward any listing pairing “clinically proven” language with four rodent papers. Treat a potency multiplier in a product description as a marketing decision, not a finding. (Disclosure: some links on this site are affiliate links; they don’t change what we report.) Our vendor reviews show what passing documentation looks like, and our lab testing explainer covers how to read a COA.

US Regulatory Status

Dihexa is not an approved drug and has never been evaluated by the FDA for any purpose. There is no prescription version; it lives in the research-chemical channel, where vials and capsules sell for non-human research use with no regulatory review of identity, purity, or safety. On the conflict-of-interest side, the 2014 mechanism paper listed authors affiliated with a Seattle biotechnology company alongside their university appointments (PMID 25187433); the independent 2021 mouse study declares none. We found no registered clinical development program that would fill this page’s gaps with human data. If that changes, it changes here first.

Frequently Asked Questions

What are the side effects of dihexa?

Unknown, literally. No human study of dihexa has ever been published, so no side-effect rates exist. The four published papers are rodent and cell studies built to measure cognitive improvement, not harm. Side-effect lists elsewhere are uncited, because there is no source.

Is dihexa safe?

No published data answers that in either direction. Nothing documents harm and nothing demonstrates safety, because the compound has never been through a study capable of measuring either. Two of its four papers carry journal flags.

Was a dihexa study retracted?

Yes. The 2014 paper establishing dihexa’s HGF/c-Met mechanism is flagged as a retracted article, with the retraction notice published in 2025 and an expression of concern from 2021. The 2013 paper that produced dihexa carries one too.

Does dihexa cause cancer or tumor growth?

No published dihexa study reports a proliferative harm, and no published dihexa study looked for one. Its reported mechanism amplifies the HGF/c-Met growth-factor system; the four papers ran cognitive and neuroinflammatory endpoints only. Unexamined, not answered.

What dose of dihexa did the studies use?

None of the four abstracts states a dose. The 2021 mouse study says only that researchers used different doses in APP/PS1 mice, orally administered. The systematic review notes the family works best administered directly into the brain’s ventricles.

Where does the dihexa potency claim come from?

Not from its own literature. No potency multiplier appears in any of the four papers behind this compound. The abstracts describe its activity qualitatively: excellent antidementia activity in rat models, synaptogenesis similar to HGF itself. The rest is product copy.

Glossary of Terms

• Dihexa: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, a metabolically stabilized, orally active analog of angiotensin IV.
• Angiotensin IV: an endogenous peptide of the brain renin-angiotensin system; dihexa’s parent molecule.
• HGF/c-Met: hepatocyte growth factor and its receptor — the growth-factor system dihexa’s retracted mechanism paper reported it amplifies.
• Morris water maze: the rodent spatial-learning test behind nearly every cognitive claim about dihexa; a behavioral endpoint, not a safety one.
• APP/PS1 mouse: a transgenic mouse model of Alzheimer’s pathology, used in the independent 2021 study.
• Expression of concern: a formal journal notice that questions have been raised about a paper, short of retracting it.
• Pharmacovigilance: the surveillance that turns real-world side effects into recorded data; nonexistent for dihexa.

References

• Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents — J Pharmacol Exp Ther, 2013 (PubMed)
• The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system — J Pharmacol Exp Ther, 2014; retracted 2025 (PubMed)
• AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway — Brain Sci, 2021 (PubMed)
• Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies — Neurosci Biobehav Rev, 2018 (PubMed)